Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States. This significant company milestone comes on the heels of Pathway’s recent launch of the Jetstream G2™ NXT, a 7 French compatible version of its peripheral revascularization catheter. Pathway’s transformational technology will be on display at TCT 2009, taking place September 21-25, 2009 at the Moscone Center in San Francisco.
“The number of patients in the U.S. afflicted with PVD is expected to grow exponentially over the next 10 years,” said Pathway Medical Technologies President and CEO Paul Buckman. “Our newest products, including Jetstream G2 NXT with 7 French compatibility, demonstrate our continued commitment to delivering best-in-class revascularization solutions for the PVD market. The fact that physicians and patients alike are embracing Jetstream as an effective, first-line treatment option to remove all types of hard and soft tissue plaque underscores its clinical utility and versatility. We are excited about the momentum achieved in the past 12 months and look forward to securing our place as the leader in PVD innovations in the months to come.”
Jetstream G2 NXT is based on Pathway’s state-of-the-art catheter technology capable of treating the entire spectrum of disease found in patients suffering from PVD, including calcium, soft plaque, fibrotic lesions and thrombus. 7 French compatibility allows physicians to use Jetstream G2 NXT in the treatment of PVD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology.
Pathway Medical Technologies, Inc. will exhibit at TCT 2009 in booth #800. Media interested in meeting with Pathway at the conference should contact Marisa Borgasano or Rebecca Phillips at Schwartz Communications, (415) 512-0770 or [email protected].
Three common cardiovascular diseases linked to cognitive impairment and dementia risk